{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T03:12:04Z","timestamp":1791774724484,"version":"4.3.4"},"reference-count":162,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2021,4,6]],"date-time":"2021-04-06T00:00:00Z","timestamp":1617667200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005795","name":"Chang Gung Memorial Hospital, Linkou","doi-asserted-by":"publisher","award":["CMRPG3J1342, CMRPG3G1281-2, CMRPG3K0841-2, CMRPG3I0271-2"],"award-info":[{"award-number":["CMRPG3J1342, CMRPG3G1281-2, CMRPG3K0841-2, CMRPG3I0271-2"]}],"id":[{"id":"10.13039\/501100005795","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001868","name":"National Science Council","doi-asserted-by":"publisher","award":["NMRPG3H0473"],"award-info":[{"award-number":["NMRPG3H0473"]}],"id":[{"id":"10.13039\/501100001868","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011912","name":"Taipei Veterans General Hospital","doi-asserted-by":"publisher","award":["Center of Excellence for Cancer Research MOHW110-TDU-B-211-144019"],"award-info":[{"award-number":["Center of Excellence for Cancer Research MOHW110-TDU-B-211-144019"]}],"id":[{"id":"10.13039\/501100011912","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Hepatocellular carcinoma (HCC) ranks as a leading cause of common cancer and cancer-related death. The major etiology of HCC is due to chronic hepatitis virus including HBV and HCV infections. Scheduled HCC surveillance in high risk populations improves the early detection rate and the feasibility of curative treatment. However, high HCC recurrence rate still accounts for the poor prognosis of HCC patients. In this article, we critically review the pathogenesis of viral hepatitis-related hepatocellular carcinoma and the evidence of tertiary prevention efficacy by current available antiviral treatment, and discuss the knowledge gap in viral hepatitis-related HCC tertiary prevention.<\/jats:p>","DOI":"10.3390\/cancers13071729","type":"journal-article","created":{"date-parts":[[2021,4,6]],"date-time":"2021-04-06T06:05:43Z","timestamp":1617689143000},"page":"1729","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Tertiary Prevention of HCC in Chronic Hepatitis B or C Infected Patients"],"prefix":"10.3390","volume":"13","author":[{"given":"Wei","family":"Teng","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, Linkou Medical Center College of Medicine, Chang Gung University, Taiwan NO 5, Fu-Hsing Street, Kuei Shan, Taoyuan City 33305, Taiwan"},{"name":"College of Medicine, Chang Gung University, Taoyuan City 33302, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8892-3341","authenticated-orcid":false,"given":"Yen-Chun","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, Linkou Medical Center College of Medicine, Chang Gung University, Taiwan NO 5, Fu-Hsing Street, Kuei Shan, Taoyuan City 33305, Taiwan"},{"name":"College of Medicine, Chang Gung University, Taoyuan City 33302, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3706-1259","authenticated-orcid":false,"given":"Wen-Juei","family":"Jeng","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, Linkou Medical Center College of Medicine, Chang Gung University, Taiwan NO 5, Fu-Hsing Street, Kuei Shan, Taoyuan City 33305, Taiwan"},{"name":"College of Medicine, Chang Gung University, Taoyuan City 33302, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3889-7004","authenticated-orcid":false,"given":"Chien-Wei","family":"Su","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Medicine, Taipei Veterans General Hospital, Taiwan. No.201, Sec. 2, Shipai Rd., Peitou District, Taipei 11217, Taiwan"},{"name":"Hospitalist Ward, Department of Medicine, Taipei Veterans General Hospital, Taipei 11217, Taiwan"},{"name":"Department of Medicine, School of Medicine, National Yang-Ming University School of Medicine, Taipei 11217, Taiwan"},{"name":"Biomedical Science and Engineering Center, National Tsing Hua University, Hsinchu 30013, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,4,6]]},"reference":[{"key":"ref_1","unstructured":"WHO (2018, September 12). Latest Global Cancer Data: Cancer Burden Rises to 19.1 Million New Cases and 9.6 Million Cancer Deaths in 2018. Available online: https:\/\/www.who.int\/cancer\/PRGlobocanFinal.pdf."},{"key":"ref_2","unstructured":"Singal, A.G., Lok, A.S., Feng, Z., Kanwal, F., and Parikh, N.D. (2020). Conceptual Model for the Hepatocellular Carcinoma Screening Continuum: Current Status and Research Agenda. Clin. Gastroenterol. Hepatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1093\/jnci\/djn243","article-title":"Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma","volume":"100","author":"Yang","year":"2008","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.1007\/s10620-020-06550-6","article-title":"Does Hepatocellular Carcinoma Surveillance Increase Survival in At-Risk Populations? Patient Selection, Biomarkers, and Barriers","volume":"65","author":"Deng","year":"2020","journal-title":"Dig. Dis. Sci."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1055\/s-2007-1007122","article-title":"Prognosis of hepatocellular carcinoma: The BCLC staging classification","volume":"19","author":"Llovet","year":"1999","journal-title":"Semin. Liver Dis."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"(1994). Predictive factors for long term prognosis after partial hepatectomy for patients with hepatocellular carcinoma in Japan. The Liver Cancer Study Group of Japan. Cancer, 74, 2772\u20132780.","DOI":"10.1002\/1097-0142(19941115)74:10<2772::AID-CNCR2820741006>3.0.CO;2-V"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1002\/bjs.1800830610","article-title":"Resection of hepatocellular carcinoma in patients with cirrhosis","volume":"83","author":"Balsells","year":"1996","journal-title":"Br. J. Surg."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1002\/jso.10178","article-title":"Prognostic factors of hepatic resection for hepatocellular carcinoma with cirrhosis: Univariate and multivariate analysis","volume":"81","author":"Yeh","year":"2002","journal-title":"J. Surg. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/S0140-6736(11)61347-0","article-title":"Hepatocellular carcinoma","volume":"379","author":"Forner","year":"2012","journal-title":"Lancet"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1002\/bjs.7669","article-title":"Systematic review and meta-analysis of survival and disease recurrence after radiofrequency ablation for hepatocellular carcinoma","volume":"98","author":"Tiong","year":"2011","journal-title":"Br. J. Surg."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1001\/archsurg.2011.288","article-title":"The effect of age on the long-term prognosis of patients with hepatocellular carcinoma after resection surgery: A propensity score matching analysis","volume":"147","author":"Su","year":"2012","journal-title":"Arch. Surg."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1002\/hep.27745","article-title":"The role of hepatic resection in the treatment of hepatocellular cancer","volume":"62","author":"Roayaie","year":"2015","journal-title":"Hepatology"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1016\/j.jhep.2018.08.027","article-title":"Development of pre and post-operative models to predict early recurrence of hepatocellular carcinoma after surgical resection","volume":"69","author":"Chan","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.jhep.2019.11.017","article-title":"Advances in resection and transplantation for hepatocellular carcinoma","volume":"72","author":"Vibert","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/ajg.2011.425","article-title":"Radiofrequency ablation for hepatocellular carcinoma: 10-year outcome and prognostic factors","volume":"107","author":"Shiina","year":"2012","journal-title":"Am. J. Gastroenterol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1148\/radiol.2017162382","article-title":"Hepatocellular Carcinoma: Nomograms Based on the Albumin-Bilirubin Grade to Assess the Outcomes of Radiofrequency Ablation","volume":"285","author":"Kao","year":"2017","journal-title":"Radiology"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.jhep.2009.07.009","article-title":"Risk factors for early and late recurrence in hepatitis B-related hepatocellular carcinoma","volume":"51","author":"Wu","year":"2009","journal-title":"J. Hepatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1053\/gast.2000.9373","article-title":"Chromosomal changes and clonality relationship between primary and recurrent hepatocellular carcinoma","volume":"119","author":"Chen","year":"2000","journal-title":"Gastroenterology"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1111\/j.1572-0241.2008.01872.x","article-title":"Recurrence of hepatitis B-related hepatocellular carcinoma is associated with high viral load at the time of resection","volume":"103","author":"Hung","year":"2008","journal-title":"Am. J. Gastroenterol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1159\/000488779","article-title":"Preoperative Visceral Adiposity and Muscularity Predict Poor Outcomes after Hepatectomy for Hepatocellular Carcinoma","volume":"8","author":"Hamaguchi","year":"2019","journal-title":"Liver Cancer"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Su, C.W., Chiou, Y.W., Tsai, Y.H., Teng, R.D., Chau, G.Y., Lei, H.J., Hung, H.H., Huo, T.I., and Wu, J.C. (2013). The Influence of Hepatitis B Viral Load and Pre-S Deletion Mutations on Post-Operative Recurrence of Hepatocellular Carcinoma and the Tertiary Preventive Effects by Anti-Viral Therapy. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0066457"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1245\/s10434-014-4221-5","article-title":"Impact of Steatosis on Prognosis of Patients with Early-Stage Hepatocellular Carcinoma After Hepatic Resection","volume":"22","author":"Su","year":"2015","journal-title":"Ann. Surg. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.jhep.2018.10.022","article-title":"Role of liver and spleen stiffness in predicting the recurrence of hepatocellular carcinoma after resection","volume":"70","author":"Marasco","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1097\/MEG.0000000000001193","article-title":"Esophageal varices are not predictive of patient prognosis after surgical resection of hepatocellular carcinoma","volume":"30","author":"Chang","year":"2018","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1245\/s10434-014-4043-5","article-title":"High levels of hepatitis B surface antigen are associated with poorer survival and early recurrence of hepatocellular carcinoma in patients with low hepatitis B viral loads","volume":"22","author":"Liu","year":"2015","journal-title":"Ann. Surg. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1245\/s10434-014-3621-x","article-title":"HBV DNA and HBsAg levels as risk predictors of early and late recurrence after curative resection of HBV-related hepatocellular carcinoma","volume":"21","author":"Sohn","year":"2014","journal-title":"Ann. Surg. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Nahm, J.H., Lee, H.S., Kim, H., Yim, S.Y., Shin, J.H., Yoo, J.E., Ahn, S.H., Choi, J.S., Lee, J.S., and Park, Y.N. (2021). Pathologic Predictive Factors for Late Recurrence of Hepatocellular Carcinoma in Chronic Liver Disease. Liver Int.","DOI":"10.1111\/liv.14835"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1086\/592990","article-title":"Combined mutations in pre-s\/surface and core promoter\/precore regions of hepatitis B virus increase the risk of hepatocellular carcinoma: A case-control study","volume":"198","author":"Chen","year":"2008","journal-title":"J. Infect. Dis."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1111\/j.1478-3231.2012.02826.x","article-title":"Fine mapping of hepatitis B virus pre-S deletion and its association with hepatocellular carcinoma","volume":"32","author":"Kao","year":"2012","journal-title":"Liver Int."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"181","DOI":"10.4132\/jptm.2016.03.18","article-title":"Nuclear Expression of Hepatitis B Virus X Protein Is Associated with Recurrence of Early-Stage Hepatocellular Carcinomas: Role of Viral Protein in Tumor Recurrence","volume":"50","author":"Jin","year":"2016","journal-title":"J. Pathol. Transl. Med."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Li, C.L., Ho, M.C., Lin, Y.Y., Tzeng, S.T., Chen, Y.J., Pai, H.Y., Wang, Y.C., Chen, C.L., Lee, Y.H., and Chen, D.S. (2020). Cell-Free Virus-Host Chimera DNA From Hepatitis B Virus Integration Sites as a Circulating Biomarker of Hepatocellular Cancer. Hepatology.","DOI":"10.1002\/hep.31230"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1007\/s00535-011-0415-9","article-title":"Hepatitis B virus X gene and hepatocarcinogenesis","volume":"46","author":"Ng","year":"2011","journal-title":"J. Gastroenterol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"198264","DOI":"10.1016\/j.virusres.2020.198264","article-title":"Partial abrogation of FXR-KNG1 signaling by carboxyl-terminal truncated HBx-C30 in hepatitis B virus-associated hepatocellular carcinoma","volume":"293","author":"Niu","year":"2021","journal-title":"Virus Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1093\/carcin\/bgr296","article-title":"Aberrant cyclin A expression and centrosome overduplication induced by hepatitis B virus pre-S2 mutants and its implication in hepatocarcinogenesis","volume":"33","author":"Wang","year":"2012","journal-title":"Carcinogenesis"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1002\/path.4850","article-title":"Expression of a hepatitis B virus pre-S2 deletion mutant in the liver results in hepatomegaly and hepatocellular carcinoma in mice","volume":"241","author":"Teng","year":"2017","journal-title":"J. Pathol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1002\/hep.29790","article-title":"Hepatitis B virus surface gene pre-S-2 mutant as a high-risk serum marker for hepatoma recurrence after curative hepatic resection","volume":"68","author":"Yen","year":"2018","journal-title":"Hepatology"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Hsu, C.W., Chu, Y.D., Lai, M.W., Lin, C.L., Liang, K.H., Lin, Y.H., and Yeh, C.T. (2021). Hepatitis B Virus Covalently Closed Circular DNA Predicts Postoperative Liver Cancer Metastasis Independent of Virological Suppression. Cancers, 13.","DOI":"10.3390\/cancers13030538"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s12072-017-9807-0","article-title":"Impact of etiological treatment on prognosis","volume":"12","author":"Su","year":"2018","journal-title":"Hepatol. Int."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1056\/NEJMoa040431","article-title":"Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B","volume":"351","author":"Marcellin","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/cncr.20004","article-title":"Prospective randomized controlled study of interferon-alpha in preventing hepatocellular carcinoma recurrence after medical ablation therapy for primary tumors","volume":"100","author":"Lin","year":"2004","journal-title":"Cancer"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1002\/jso.21741","article-title":"Interferon-alpha therapy after curative resection prevents early recurrence and improves survival in patients with hepatitis B virus-related hepatocellular carcinoma","volume":"102","author":"Qu","year":"2010","journal-title":"J. Surg. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1007\/s00432-006-0091-y","article-title":"Postoperative interferon alpha treatment postponed recurrence and improved overall survival in patients after curative resection of HBV-related hepatocellular carcinoma: A randomized clinical trial","volume":"132","author":"Sun","year":"2006","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1097\/01.sla.0000245829.00977.45","article-title":"A randomized, controlled trial of postoperative adjuvant interferon therapy after resection of hepatocellular carcinoma","volume":"245","author":"Lo","year":"2007","journal-title":"Ann. Surg."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/SLA.0b013e3182363ff9","article-title":"Long-term results of a randomized, observation-controlled, phase III trial of adjuvant interferon Alfa-2b in hepatocellular carcinoma after curative resection","volume":"255","author":"Chen","year":"2012","journal-title":"Ann. Surg."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/hepr.12115","article-title":"Antiviral therapy after curative treatment of hepatitis B\/C virus-related hepatocellular carcinoma: A systematic review of randomized trials","volume":"44","author":"Sun","year":"2014","journal-title":"Hepatol. Res."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/jvh.13236","article-title":"Peg-interferon and nucleos(t)ide analogue combination at inception of antiviral therapy improves both anti-HBV efficacy and long-term survival among HBV DNA-positive hepatocellular carcinoma patients after hepatectomy\/ablation","volume":"27","author":"Qi","year":"2020","journal-title":"J. Viral Hepat."},{"key":"ref_47","unstructured":"Surveillance Group, Diagnosis Group, Staging Group, Surgery Group, Local Ablation Group, TACE\/TARE\/HAI Group, Target Therapy\/Systemic Therapy Group, Radiotherapy Group, Prevention Group, and Drafting Group (2018). Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan. J. Formos. Med Assoc., 117, 381\u2013403."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/S0140-6736(12)61425-1","article-title":"Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: A 5-year open-label follow-up study","volume":"381","author":"Marcellin","year":"2013","journal-title":"Lancet"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/jvh.13040","article-title":"The impact of currently licensed therapies on viral and immune responses in chronic hepatitis B: Considerations for future novel therapeutics","volume":"26","author":"Gill","year":"2019","journal-title":"J. Viral Hepat."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1056\/NEJMoa033364","article-title":"Lamivudine for patients with chronic hepatitis B and advanced liver disease","volume":"351","author":"Liaw","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1111\/liv.13253","article-title":"Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients","volume":"36","author":"Su","year":"2016","journal-title":"Liver Int."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1053\/j.gastro.2014.03.048","article-title":"Association of nucleos(t)ide analogue therapy with reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B: A nationwide cohort study","volume":"147","author":"Wu","year":"2014","journal-title":"Gastroenterology"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1111\/apt.13774","article-title":"Reduction of chronic hepatitis B-related hepatocellular carcinoma with anti-viral therapy, including low risk patients","volume":"44","author":"Lin","year":"2016","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1111\/apt.13548","article-title":"Oral nucleos(t)ide analogues reduce recurrence and death in chronic hepatitis B-related hepatocellular carcinoma","volume":"43","author":"Wong","year":"2016","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1007\/s12072-015-9647-8","article-title":"Effects of long-term entecavir treatment on the incidence of hepatocellular carcinoma in chronic hepatitis B patients","volume":"10","author":"Watanabe","year":"2016","journal-title":"Hepatol. Int."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1001\/archsurg.2011.125","article-title":"Impact of antiviral therapy on the survival of patients after major hepatectomy for hepatitis B virus-related hepatocellular carcinoma","volume":"146","author":"Chan","year":"2011","journal-title":"Arch. Surg."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1001\/2012.jama.11975","article-title":"Association between nucleoside analogues and risk of hepatitis B virus-related hepatocellular carcinoma recurrence following liver resection","volume":"308","author":"Wu","year":"2012","journal-title":"JAMA"},{"key":"ref_59","first-page":"158","article-title":"Antiviral therapy for hepatitis B virus-related hepatocellular carcinoma after radical hepatectomy","volume":"10","author":"Ke","year":"2013","journal-title":"Cancer Biol. Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"3647","DOI":"10.1200\/JCO.2012.48.5896","article-title":"Effect of antiviral treatment with nucleotide\/nucleoside analogs on postoperative prognosis of hepatitis B virus-related hepatocellular carcinoma: A two-stage longitudinal clinical study","volume":"31","author":"Yin","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Sun, P., Dong, X., Cheng, X., Hu, Q., and Zheng, Q. (2014). Nucleot(s)ide analogues for hepatitis B virus-related hepatocellular carcinoma after curative treatment: A systematic review and meta-analysis. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0102761"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1097\/SLA.0000000000000858","article-title":"Antiviral therapy improves postoperative survival in patients with hepatocellular carcinoma: A randomized controlled trial","volume":"261","author":"Huang","year":"2015","journal-title":"Ann. Surg"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/apt.13034","article-title":"Antiviral therapy improves post-hepatectomy survival in patients with hepatitis B virus-related hepatocellular carcinoma: A prospective-retrospective study","volume":"41","author":"Chong","year":"2015","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1002\/hep.28266","article-title":"Association between nucleos(t)ide analog and tumor recurrence in hepatitis B virus-related hepatocellular carcinoma after radiofrequency ablation","volume":"63","author":"Lee","year":"2016","journal-title":"Hepatology"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"5363","DOI":"10.2147\/OTT.S150281","article-title":"The effect of antiviral therapy on patients with hepatitis B virus-related hepatocellular carcinoma after curative resection: A systematic review and meta-analysis","volume":"10","author":"Chen","year":"2017","journal-title":"OncoTargets Ther."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"100152","DOI":"10.1016\/j.jhepr.2020.100152","article-title":"Increasing antiviral treatment uptake improves survival in patients with HBV-related HCC","volume":"2","author":"Hui","year":"2020","journal-title":"JHEP Rep."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1111\/jvh.12855","article-title":"Entecavir and tenofovir reduce hepatitis B virus-related hepatocellular carcinoma recurrence more effectively than other antivirals","volume":"25","author":"Cho","year":"2018","journal-title":"J. Viral Hepat."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Choi, J., Jo, C., and Lim, Y.S. (2020). Tenofovir Versus Entecavir on Recurrence of Hepatitis B Virus-Related Hepatocellular Carcinoma After Surgical Resection. Hepatology.","DOI":"10.1002\/hep.31289"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jfma.2018.11.008","article-title":"Taiwan consensus statement on the management of chronic hepatitis B","volume":"118","author":"Chien","year":"2019","journal-title":"J. Formos. Med. Assoc."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Yeh, C.T., Chen, T., Hsu, C.W., Chen, Y.C., Lai, M.W., Liang, K.H., and Chen, T.C. (2011). Emergence of the rtA181T\/sW172* mutant increased the risk of hepatoma occurrence in patients with lamivudine-resistant chronic hepatitis B. BMC Cancer, 11.","DOI":"10.1186\/1471-2407-11-398"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.jhep.2018.10.014","article-title":"HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues","volume":"70","author":"Yip","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1007\/s10620-019-05518-5","article-title":"What Comes First: Treatment of Viral Hepatitis or Liver Cancer?","volume":"64","author":"Feld","year":"2019","journal-title":"Dig. Dis. Sci."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1002\/cncr.31551","article-title":"Annual Report to the Nation on the Status of Cancer, part I: National cancer statistics","volume":"124","author":"Cronin","year":"2018","journal-title":"Cancer"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/nrgastro.2016.176","article-title":"Global epidemiology and burden of HCV infection and HCV-related disease","volume":"14","author":"Thrift","year":"2017","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.dld.2010.05.006","article-title":"Forecasting the morbidity and mortality associated with prevalent cases of pre-cirrhotic chronic hepatitis C in the United States","volume":"43","author":"Rein","year":"2011","journal-title":"Dig. Liver Dis."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"S79","DOI":"10.1016\/j.jhep.2014.07.010","article-title":"Pathogenesis and prevention of hepatitis C virus-induced hepatocellular carcinoma","volume":"61","author":"Hoshida","year":"2014","journal-title":"J. Hepatol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.chom.2014.02.011","article-title":"Human viral oncogenesis: A cancer hallmarks analysis","volume":"15","author":"Mesri","year":"2014","journal-title":"Cell Host Microbe"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.jhep.2012.06.027","article-title":"Hepatitis C viral protein NS5A induces EMT and participates in oncogenic transformation of primary hepatocyte precursors","volume":"57","author":"Akkari","year":"2012","journal-title":"J. Hepatol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.clinre.2015.07.006","article-title":"TERT promoter mutations in primary liver tumors","volume":"40","author":"Nault","year":"2016","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"key":"ref_80","first-page":"323926","article-title":"Treatment of hepatitis C infections with interferon: A historical perspective","volume":"2010","author":"Friedman","year":"2010","journal-title":"Hepat. Res. Treat."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","article-title":"Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial","volume":"358","author":"Manns","year":"2001","journal-title":"Lancet"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa020047","article-title":"Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection","volume":"347","author":"Fried","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/nature04082","article-title":"Mechanism of action of interferon and ribavirin in treatment of hepatitis C","volume":"436","author":"Feld","year":"2005","journal-title":"Nature"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1146\/annurev.biochem.67.1.227","article-title":"How cells respond to interferons","volume":"67","author":"Stark","year":"1998","journal-title":"Annu. Rev. Biochem."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"4313","DOI":"10.1182\/blood.V96.13.4313","article-title":"Interferon \u03b1 down-regulates telomerase reverse transcriptase and telomerase activity in human malignant and nonmalignant hematopoietic cells","volume":"96","author":"Xu","year":"2000","journal-title":"Blood"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1007\/s00535-005-1616-x","article-title":"Differential effects of interferon alpha-2b and beta on the signaling pathways in human liver cancer cells","volume":"40","author":"Matsumoto","year":"2005","journal-title":"J. Gastroenterol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1056\/NEJM199804303381805","article-title":"Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma","volume":"338","author":"Negrier","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1002\/hep.510290624","article-title":"Interferon alfa receptor expression and growth inhibition by interferon alfa in human liver cancer cell lines","volume":"29","author":"Yano","year":"1999","journal-title":"Hepatology"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/nrc2389","article-title":"Wnt signalling and its impact on development and cancer","volume":"8","author":"Klaus","year":"2008","journal-title":"Nat. Rev. Cancer"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.2174\/092986710793176393","article-title":"The anticancer face of interferon alpha (IFN-alpha): From biology to clinical results, with a focus on melanoma","volume":"17","author":"Pasquali","year":"2010","journal-title":"Curr. Med. Chem."},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Villani, R., Vendemiale, G., and Serviddio, G. (2018). Molecular Mechanisms Involved in HCC Recurrence after Direct-Acting Antiviral Therapy. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20010049"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1111\/jvh.12465","article-title":"Memory re-differentiation and reduced lymphocyte activation in chronic HCV-infected patients receiving direct-acting antivirals","volume":"22","author":"Burchill","year":"2015","journal-title":"J. Viral Hepat."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.jhep.2014.05.043","article-title":"Restoration of HCV-specific CD8+ T cell function by interferon-free therapy","volume":"61","author":"Martin","year":"2014","journal-title":"J. Hepatol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1002\/eji.201646447","article-title":"Nonreversible MAIT cell-dysfunction in chronic hepatitis C virus infection despite successful interferon-free therapy","volume":"46","author":"Hengst","year":"2016","journal-title":"Eur. J. Immunol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.jhep.2016.12.019","article-title":"Increased peripheral CD4(+) regulatory T cells persist after successful direct-acting antiviral treatment of chronic hepatitis C","volume":"66","author":"Langhans","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Dilek, N., Poirier, N., Hulin, P., Coulon, F., Mary, C., Ville, S., Vie, H., Clemenceau, B., Blancho, G., and Vanhove, B. (2013). Targeting CD28, CTLA-4 and PD-L1 costimulation differentially controls immune synapses and function of human regulatory and conventional T-cells. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0083139"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1053\/j.gastro.2015.03.004","article-title":"Successful Interferon-Free Therapy of Chronic Hepatitis C Virus Infection Normalizes Natural Killer Cell Function","volume":"149","author":"Serti","year":"2015","journal-title":"Gastroenterology"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.imbio.2015.07.012","article-title":"Tricking the balance: NK cells in anti-cancer immunity","volume":"222","author":"Pahl","year":"2017","journal-title":"Immunobiology"},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Chu, P.S., Nakamoto, N., Taniki, N., Ojiro, K., Amiya, T., Makita, Y., Murata, H., Yamaguchi, A., Shiba, S., and Miyake, R. (2017). On-treatment decrease of NKG2D correlates to early emergence of clinically evident hepatocellular carcinoma after interferon-free therapy for chronic hepatitis C. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0179096"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.jcmgh.2015.09.004","article-title":"Natural Killer Cells in Viral Hepatitis","volume":"1","author":"Rehermann","year":"2015","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1053\/j.gastro.2017.10.035","article-title":"Levels of Cytokines in Serum Associate With Development of Hepatocellular Carcinoma in Patients With HCV Infection Treated With Direct-Acting Antivirals","volume":"154","author":"Debes","year":"2018","journal-title":"Gastroenterology"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1053\/j.gastro.2019.02.038","article-title":"HCV-Induced Epigenetic Changes Associated With Liver Cancer Risk Persist After Sustained Virologic Response","volume":"156","author":"Hamdane","year":"2019","journal-title":"Gastroenterology"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1002\/hep.29911","article-title":"Liver Angiopoietin-2 Is a Key Predictor of De Novo or Recurrent Hepatocellular Cancer After Hepatitis C Virus Direct-Acting Antivirals","volume":"68","author":"Faillaci","year":"2018","journal-title":"Hepatology"},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Itami-Matsumoto, S., Hayakawa, M., Uchida-Kobayashi, S., Enomoto, M., Tamori, A., Mizuno, K., Toyoda, H., Tamura, T., Akutsu, T., and Ochiya, T. (2019). Circulating Exosomal miRNA Profiles Predict the Occurrence and Recurrence of Hepatocellular Carcinoma in Patients with Direct-Acting Antiviral-Induced Sustained Viral Response. Biomedicines, 7.","DOI":"10.3390\/biomedicines7040087"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1053\/gast.2002.33023","article-title":"Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C","volume":"122","author":"Poynard","year":"2002","journal-title":"Gastroenterology"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/hep.26300","article-title":"Postoperative peg-interferon plus ribavirin is associated with reduced recurrence of hepatitis C virus-related hepatocellular carcinoma","volume":"58","author":"Hsu","year":"2013","journal-title":"Hepatology"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.jfma.2018.11.014","article-title":"Timely eradication of HCV viremia by PegIFN\/RBV is crucial in prevention of post RFA recurrence in CHC-HCC patients","volume":"118","author":"Chen","year":"2019","journal-title":"J. Formos. Med. Assoc."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1111\/jvh.12745","article-title":"Eradication of hepatitis C virus profoundly prolongs survival in hepatocellular carcinoma patients receiving transarterial chemoembolization","volume":"24","author":"Teng","year":"2017","journal-title":"J. Viral Hepat."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1111\/jgh.13012","article-title":"The tertiary prevention of hepatocellular carcinoma in chronic hepatitis C patients","volume":"30","author":"Huang","year":"2015","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"Zhuang, L., Zeng, X., Yang, Z., and Meng, Z. (2013). Effect and safety of interferon for hepatocellular carcinoma: A systematic review and meta-analysis. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0061361"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1002\/ijc.30521","article-title":"Impact of sustained viral response postcurative therapy of hepatitis C-related hepatocellular carcinoma: A systematic review and meta-analysis","volume":"140","author":"Manthravadi","year":"2017","journal-title":"Int. J. Cancer"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1002\/hep.21415","article-title":"Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis","volume":"44","author":"Mazzaferro","year":"2006","journal-title":"Hepatology"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1159\/000111719","article-title":"Long-term interferon maintenance therapy improves survival in patients with HCV-related hepatocellular carcinoma after curative radiofrequency ablation","volume":"72","author":"Kudo","year":"2007","journal-title":"Oncology"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"5343","DOI":"10.3748\/wjg.v13.i40.5343","article-title":"Effects of a 24-week course of interferon-\u03b1 therapy after curative treatment of hepatitis C virus-associated hepatocellular carcinoma","volume":"13","author":"Jeong","year":"2007","journal-title":"World, J. Gastroenterol. WJG"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1111\/jgh.12925","article-title":"Sustained virologic response achieved after curative treatment of hepatitis C virus-related hepatocellular carcinoma as an independent prognostic factor","volume":"30","author":"Kanogawa","year":"2015","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/apt.13821","article-title":"Hepatocellular carcinoma recurrence in patients with curative resection or ablation: Impact of HCV eradication does not depend on the use of interferon","volume":"45","author":"Petta","year":"2017","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1053\/j.gastro.2018.10.024","article-title":"Status of Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection and Remaining Challenges","volume":"156","author":"Baumert","year":"2019","journal-title":"Gastroenterology"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1111\/jvh.12578","article-title":"Regression of fibrosis and portal hypertension in HCV-associated cirrhosis and sustained virologic response after interferon-free antiviral therapy","volume":"23","author":"Knop","year":"2016","journal-title":"J. Viral Hepat."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/j.jhep.2016.01.029","article-title":"Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis","volume":"64","author":"Foster","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/apt.13823","article-title":"All-oral direct-acting antiviral therapy in HCV-advanced liver disease is effective in real-world practice: Observations through HCV-TARGET database","volume":"45","author":"Reddy","year":"2017","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.jhep.2016.04.008","article-title":"Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy","volume":"65","author":"Reig","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.jhep.2016.06.015","article-title":"Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals","volume":"65","author":"Conti","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"194","DOI":"10.5114\/ceh.2017.71483","article-title":"Accelerated hepatocellular carcinoma recurrence rate after postoperative direct-acting antivirals treatment\u2014preliminary report","volume":"3","author":"Warzyszynska","year":"2017","journal-title":"Clin. Exp. Hepatol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1111\/apt.14256","article-title":"Is early recurrence of hepatocellular carcinoma in HCV cirrhotic patients affected by treatment with direct-acting antivirals? A prospective multicentre study","volume":"46","author":"Cabibbo","year":"2017","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/apt.14380","article-title":"Short-term risk of hepatocellular carcinoma after hepatitis C virus eradication following direct-acting anti-viral treatment","volume":"47","author":"Ogawa","year":"2018","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/j.jhep.2017.01.028","article-title":"Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort","volume":"66","author":"Calleja","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1002\/cam4.2061","article-title":"Predictors of hepatocellular carcinoma recurrence associated with the use of direct-acting antiviral agent therapy for hepatitis C virus after curative treatment: A prospective multicenter cohort study","volume":"8","author":"Nakano","year":"2019","journal-title":"Cancer Med."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1111\/jvh.12726","article-title":"The risk of early occurrence and recurrence of hepatocellular carcinoma in hepatitis C-infected patients treated with direct-acting antivirals with and without pegylated interferon: A Belgian experience","volume":"24","author":"Bielen","year":"2017","journal-title":"J. Viral Hepat."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.jhep.2016.06.019","article-title":"Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis","volume":"65","author":"Cheung","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"63","DOI":"10.15403\/jgld.2014.1121.281.hpc","article-title":"Predictive factors for hepatocellular carcinoma occurrence or recurrence after direct-acting antiviral agents in patients with chronic hepatitis C","volume":"28","author":"Yoshimasu","year":"2019","journal-title":"J. Gastrointestin. Liver Dis."},{"key":"ref_131","doi-asserted-by":"crossref","unstructured":"The ANRS Collaborative Study Group on Hepatocellular Carcinoma (2016). Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: Data from three ANRS cohorts. J. Hepatol., 65, 734\u2013740.","DOI":"10.1016\/j.jhep.2016.05.045"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.jhep.2017.07.007","article-title":"Hepatocellular carcinoma recurrence after direct antiviral agent treatment: A European multicentre study","volume":"67","author":"Kolly","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1111\/liv.13456","article-title":"Direct-acting antiviral therapy decreases hepatocellular carcinoma recurrence rate in cirrhotic patients with chronic hepatitis C","volume":"37","author":"Virlogeux","year":"2017","journal-title":"Liver Int."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.jhep.2016.08.016","article-title":"Is the risk of neoplastic recurrence increased after prescribing direct-acting antivirals for HCV patients whose HCC was previously cured?","volume":"66","author":"Zavaglia","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"2932","DOI":"10.1007\/s10620-017-4739-z","article-title":"Direct-Acting Antivirals Decreased Tumor Recurrence After Initial Treatment of Hepatitis C Virus-Related Hepatocellular Carcinoma","volume":"62","author":"Ikeda","year":"2017","journal-title":"Dig. Dis. Sci."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/apt.14823","article-title":"Systematic review with meta-analysis: Recurrence of hepatocellular carcinoma following direct-acting antiviral therapy","volume":"48","author":"Saraiya","year":"2018","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1136\/flgastro-2018-101017","article-title":"Oral direct-acting antivirals and the incidence or recurrence of hepatocellular carcinoma: A systematic review and meta-analysis","volume":"9","author":"Singh","year":"2018","journal-title":"Frontline Gastroenterol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1002\/hep.29855","article-title":"Direct-acting antivirals do not increase the risk of hepatocellular carcinoma recurrence after local-regional therapy or liver transplant waitlist dropout","volume":"68","author":"Huang","year":"2018","journal-title":"Hepatology"},{"key":"ref_139","doi-asserted-by":"crossref","unstructured":"Singal, A.G., Rich, N.E., Mehta, N., Branch, A., Pillai, A., Hoteit, M., Volk, M., Odewole, M., Scaglione, S., and Guy, J. (2019). Direct-Acting Antiviral Therapy Not Associated With Recurrence of Hepatocellular Carcinoma in a Multicenter North American Cohort Study. Gastroenterology.","DOI":"10.1053\/j.gastro.2019.01.027"},{"key":"ref_140","doi-asserted-by":"crossref","unstructured":"Cabibbo, G., Celsa, C., Calvaruso, V., Petta, S., Cacciola, I., Cannav\u00f2, M.R., Madonia, S., Rossi, M., Magro, B., and Rini, F. (2019). Direct acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients. J. Hepatol.","DOI":"10.1016\/j.dld.2018.11.104"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1016\/j.jhep.2016.07.043","article-title":"The impact of direct-acting antivirals on early tumor recurrence after radiofrequency ablation in hepatitis C-related hepatocellular carcinoma","volume":"65","author":"Minami","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_142","doi-asserted-by":"crossref","unstructured":"Nishibatake Kinoshita, M., Minami, T., Tateishi, R., Wake, T., Nakagomi, R., Fujiwara, N., Sato, M., Uchino, K., Enooku, K., and Nakagawa, H. (2018). Impact of direct-acting antivirals on early recurrence of HCV-related HCC: Comparison with interferon-based therapy. J. Hepatol.","DOI":"10.1016\/j.jhep.2018.09.029"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.jhep.2017.05.028","article-title":"Effect of interferon-based and -free therapy on early occurrence and recurrence of hepatocellular carcinoma in chronic hepatitis C","volume":"67","author":"Nagata","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_144","doi-asserted-by":"crossref","unstructured":"Nagaoki, Y., Imamura, M., Nisihda, Y., Daijo, K., Teraoka, Y., Honda, F., Nakamura, Y., Morio, K., Fujino, H., and Nakahara, T. (2018). The impact of interferon-free direct-acting antivirals on clinical outcome after curative treatment for hepatitis C virus-associated hepatocellular carcinoma; comparison with interferon-based therapy. J. Med. Virol.","DOI":"10.1002\/jmv.25352"},{"key":"ref_145","doi-asserted-by":"crossref","unstructured":"Mashiba, T., Joko, K., Kurosaki, M., Ochi, H., Osaki, Y., Kojima, Y., Nakata, R., Goto, T., Takehiro, A., and Kimura, H. (2018). Does interferon-free direct-acting antiviral therapy for hepatitis C after curative treatment for hepatocellular carcinoma lead to unexpected recurrences of HCC? A multicenter study by the Japanese Red Cross Hospital Liver Study Group. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0194704"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/jvh.12854","article-title":"Increased recurrence rates of hepatocellular carcinoma after DAA therapy in a hepatitis C-infected Egyptian cohort: A comparative analysis","volume":"25","author":"Funk","year":"2018","journal-title":"J. Viral Hepat."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/j.jhep.2017.07.025","article-title":"Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression","volume":"67","author":"Waziry","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_148","doi-asserted-by":"crossref","unstructured":"Teng, W., Jeng, W.J., Yang, H.I., Chen, W.T., Hsieh, Y.C., Huang, C.H., Lin, C.C., Lin, C.Y., Lin, S.M., and Sheen, I.S. (2019). Interferon Is Superior to Direct Acting Antiviral Therapy in Tertiary Prevention of Early Recurrence of Hepatocellular Carcinoma. Cancers, 12.","DOI":"10.3390\/cancers12010023"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jhep.2017.01.033","article-title":"Hepatic decompensation is the major driver of death in HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma","volume":"67","author":"Cabibbo","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.jhep.2012.10.017","article-title":"Efficacy of pegylated interferon alpha-2b and ribavirin treatment on the risk of hepatocellular carcinoma in patients with chronic hepatitis C: A prospective, multicenter study","volume":"58","author":"Ogawa","year":"2013","journal-title":"J. Hepatol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/hep.29487","article-title":"Imaging for the diagnosis of hepatocellular carcinoma: A systematic review and meta-analysis","volume":"67","author":"Roberts","year":"2018","journal-title":"Hepatology"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1053\/j.gastro.2019.02.046","article-title":"AGA Clinical Practice Update on Interaction Between Oral Direct-Acting Antivirals for Chronic Hepatitis C Infection and Hepatocellular Carcinoma: Expert Review","volume":"156","author":"Singal","year":"2019","journal-title":"Gastroenterology"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/j.jhep.2017.01.020","article-title":"Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct-acting antivirals","volume":"66","author":"Prenner","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.jhep.2017.02.027","article-title":"Effectiveness of hepatitis C antiviral treatment in a USA cohort of veteran patients with hepatocellular carcinoma","volume":"67","author":"Beste","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","article-title":"Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): An open-label, non-comparative, phase 1\/2 dose escalation and expansion trial","volume":"389","author":"Sangro","year":"2017","journal-title":"Lancet"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S1470-2045(18)30351-6","article-title":"Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): A non-randomised, open-label phase 2 trial","volume":"19","author":"Zhu","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1200\/JCO.19.01307","article-title":"Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial","volume":"38","author":"Finn","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_159","doi-asserted-by":"crossref","unstructured":"Lee, P.-C., Chao, Y., Chen, M.-H., Lan, K.-H., Lee, I.C., Hou, M.-C., and Huang, Y.-H. (2020). Risk of HBV reactivation in patients with immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma. J. Immunother. Cancer, 8.","DOI":"10.1136\/jitc-2020-001072"},{"key":"ref_160","doi-asserted-by":"crossref","unstructured":"Wong, G.L., Wong, V.W., Hui, V.W., Yip, T.C., Tse, Y.K., Liang, L.Y., Lui, R.N., Mok, T.S., Chan, H.L., and Chan, S.L. (2021). Hepatitis Flare During Immunotherapy in Patients With Current or Past Hepatitis B Virus Infection. Am. J. Gastroenterol.","DOI":"10.14309\/ajg.0000000000001142"},{"key":"ref_161","first-page":"737389","article-title":"PD-1 Blockade in Advanced Melanoma in Patients with Hepatitis C and\/or HIV","volume":"2015","author":"Davar","year":"2015","journal-title":"Case Rep. Oncol. Med."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.lungcan.2020.02.013","article-title":"Safety and efficacy of immune checkpoint inhibitors in patients with non-small cell lung cancer and hepatitis B or hepatitis C infection","volume":"145","author":"Ricciuti","year":"2020","journal-title":"Lung Cancer"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/7\/1729\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T14:11:22Z","timestamp":1760364682000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/7\/1729"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,6]]},"references-count":162,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2021,4]]}},"alternative-id":["cancers13071729"],"URL":"https:\/\/doi.org\/10.3390\/cancers13071729","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,6]]}}}